IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.1 Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagnosis can be challenging.1,2 This year for IPF World Week (16-24 September), Boehringer Ingelheim is raising awareness of ‘the sounds of IPF’ helping physicians recognise the velcro-like crackle which can be heard in the lungs of the majority of IPF patients on auscultation.2 The goal is earlier accurate medical diagnosis which should lead to immediate initiation of treatment.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170918005646/en/
“What I hear loud and clear from patients is that a key concern for them is getting a confirmed diagnosis. Next is talking with their physician about treatment that can slow the progression of IPF. The realisation that you have IPF is shattering, and patients have to think about their future: they worry about lung function decline and they fear acute exacerbations.” Liam Galvin, Secretary of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF) (Photo: Business Wire)
Though it is a rare disease, IPF affects approximately three million people worldwide and has a devastating impact on patient lives.3 Professor Toby Maher, Royal Brompton Hospital commented: “IPF is a disease with an unpredictable course where exacerbations can occur at any time without warning. Clinical trials have shown us that patients without treatment lose lung function even when their disease is in the earliest stages. Antifibrotic treatment can reduce this decline by approximately 50%. Therefore any delay in initiating treatment puts patients at risk of irreversible loss of lung capacity”. There are two approved antifibrotic drugs shown to slow the disease progression in IPF that are recommended by international guidelines.4
Analysis of results from two global surveys sponsored by Boehringer Ingelheim involving over 400 pulmonologists and 150 patients show that patients and physicians agree that maintaining lung function for as long as possible is one of the key treatment priorities. Despite this alignment in priorities and the availability of medicines for use in IPF patients, around one in three patients (30%) do not feel involved in treatment discussions at all.5
Liam Galvin, Secretary of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF), explained: “What I hear loud and clear from patients is that a key concern for them is getting a confirmed diagnosis. Next is talking with their physician about treatment that can slow the progression of IPF. The realisation that you have IPF is shattering, and patients have to think about their future: they worry about lung function decline and they fear acute exacerbations.”
To raise awareness of the importance of ‘listening to the sounds of IPF’, Boehringer Ingelheim has created a range of educational tools. Physicians interested in learning more can visit the online resource inIPF.com. In addition, LifewithIPF.com is a platform for patients where a range of background materials, IPF patient video stories and webinars with pulmonologists can be found.
“Time is of essence. If patients can be diagnosed timely and referred to an expert pulmonologist to initiate treatment at the earliest opportunity, we stand a greater chance of making a real difference in the ongoing challenge of managing this devastating disease. We need to raise awareness for IPF and act together to help patients and their families.”, said Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Respiratory, Boehringer Ingelheim.
~ ENDS ~
Please click on the link below for ‘Notes to Editors’ and ‘References’:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AMRA Receives U.S. FDA Clearance for AMRA® Profiler, a Magnetic Resonance Diagnostic Software Application Enabling Non-Invasive Evaluation of Body Composition11.12.2018 11:28 | Pressemelding
AMRA Medical (“AMRA”), the international leader in body composition analysis, announced today that it has received FDA clearance for AMRA® Profiler, now available for use in a clinical setting in the US. AMRA® Profiler is indicated for use as a magnetic resonance (MR) diagnostic device for non-invasive fat and muscle evaluation that enables the generation, display and review of MR-based body composition measurements. AMRA is the first in the world to transform MR-images from a 6-minute whole-body MRI scan into 3D-volumetric fat and muscle measurements, enabling outstanding accuracy and precision when assessing volume and distribution of fat and muscles, as well as metabolic status. “We are delighted with the FDA’s decision. The challenges facing healthcare systems across the world are well-documented. Cost constraints, together with societal issues such as obesity and an aging population, are putting hospitals and private clinics under increasing pressure,” stated Eric Converse, CEO of
Acuris Risk Intelligence Celebrates 350 Direct Customers and Wins Compliance Awards11.12.2018 11:00 | Pressemelding
Acuris Risk Intelligence, a trusted and independent provider of data intelligence for Anti-Money Laundering, Third Party Risk and Cyber Security professionals, today announces that it now serves 350 direct customers worldwide, helping them to mitigate risk and effectively comply with regulations. This significant milestone nearly doubles its direct client base compared to this time last year and is only two months since the relaunch of the brand, formerly known as C6. Whilst the business has been successful since its inception in 2004 in selling its data via major channel partners, this is a noteworthy milestone as it reflects the success of focusing on direct customer outreach. The business continues to work with some of the biggest compliance platforms in the world as an integrated provider. Acuris Risk Intelligence has also won FinTech/RegTech Rising Star and Best Financial Crime Intelligence Data at The Compliance Register Platinum Awards 2018 as well as executing a successful expa
Wound Care: Nexodyn® AOS Comes to Fruition in Slovakia11.12.2018 10:30 | Pressemelding
Nexodyn® AcidOxidizing Solution (AOS), the Tehclo-based product for acute and chronic wound management, is now available in Slovakia, promoted and commercialized by the pharmaceutical companies Evopharm and Sanomed, pursuant to an exclusive partnership with the Swiss pharma company APR Applied Pharma Research s.a. (“APR”). After Slovakia, in early 2019 Evopharm will expand the distribution of the product first to Poland, where the registration is currently being completed, and then to Czech Republic. As confirmed by the results of pre-launch activities, Evopharm is confident that Nexodyn® AOS, based on APR’s proprietary and patented technology Tehclo®, can offer to Slovak Healthcare Professionals (“HCPs”) and caregivers a new treatment option to effectively address the wound healing complexity. Local KOLs, involved in an Advisory Board, got particularly impressed from the distinctive physico-chemical properties of this product, able to create the ideal microenvironment to sustain the p
Kao Data Invests in euNetworks High Density Fibre as Part of a North London Artery11.12.2018 09:07 | Pressemelding
Kao Data, the home of innovation and UK’s leading entrant to the wholesale colocation market, has announced it is working with euNetworks, a Western European bandwidth infrastructure provider. This enables the delivery of high-density fibre and duct to the Kao Data, Harlow based data centre campus north of London. The new infrastructure provides unique routing opportunities, taking advantage of Harlow’s strategic location between core hyperscale campuses in Dublin and Amsterdam. It also offers fast connection to Slough, to the West of London, and Docklands in the East of London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005308/en/ Kao Data Invests in euNetworks High Density Fibre as Part of a North London Artery (Photo: Business Wire) As the UK continues its strong position in the international data centre market, a series of significant investments in high-density fibre routes are underway to support hyperscale d
Spirent Helps High-Speed Setup For Aston Martin Racing11.12.2018 08:00 | Pressemelding
Spirent Communications plc (LSE:SPT), the world leader in test, measurement, assurance, and analytics solutions for next-generation devices and networks, today announced that Aston Martin Racing (AMR) is using its Test as a Service (TaaS) platform, iTest, to assist the iconic automotive brand’s bid for FIA World Endurance Championship GTE category success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005239/en/ Spirent's technical partnership with Aston Martin Racing has dramatically reduced the team's high-speed LAN test and set-up time at FIAWEC events. (Photo: Business Wire) Aston Martin Racing deploys a high-speed local area network (LAN) trackside to connect team drivers and cars with the pit crew, engineers and managers on pit lane, to carry radio communications, telemetry and video data. The FIAWEC Super Season includes some of the world’s most grueling tests of driver and car – including the famous Le Mans 24
WaveOptics Raises $26m to Scale Business and Support International Expansion in Its First Stage of Series C Funding11.12.2018 08:00 | Pressemelding
WaveOptics, the world leading designer and manufacturer of diffractive waveguides for use in Augmented Reality (AR) wearables, has raised $26 million (£20m) from existing shareholders and new investors. The capital raised will be used to scale up the business operations on a national and international basis. This round was led by Octopus Ventures, one of WaveOptics’ largest shareholders and one of Europe’s most prominent venture capital firms. The fundraise was supported by other existing shareholders including IP Group, Robert Bosch Venture Capital and Gobi Partners, as well as new investors Goertek and Optimas Capital Partners. David Hayes, WaveOptics CEO, commented: “We have made excellent progress over the last year with our high performing, manufacturable, and versatile waveguides. We are now working with a wide range of leading global OEMs and ODMs as they ramp up the development of their products. “These additional funds will enable us to scale up rapidly around the world, parti